DERMATOLOGIC ADVERSE EVENTS WITHIN THE FIRST 60 DAYS OF SORAFENIB TREATMENT ARE ASSOCIATED WITH BETTER OVERALL SURVIVAL (OS) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

被引：0
|
作者：
Reig, M. [1 ]
Rodriguez de Lope, C. [1 ]
Llarch, N. [1 ]
Forner, A. [1 ]
Torres, F. [2 ]
Rios, J. [2 ]
Boix, L. [1 ]
Rimola, J. [3 ]
Darnell, A. [3 ]
Ayuso, C. [3 ]
Bruix, J. [1 ]
机构：
[1] Univ Barcelona, BCLC Grp, Liver Unit, CIBERehd,IDIBAPS,Hosp Clin, Barcelona, Spain
[2] Univ Autonoma Barcelona, IDIBAPS, Hosp Clin Barcelona, Unidad Bioestadist,Fac Med, E-08193 Barcelona, Spain
[3] Univ Barcelona, BCLC Grp, Dept Radiol, CIBERehd,IDIBAPS,Hosp Clin, Barcelona, Spain
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60269-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
267
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [1] Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
    Reig, Maria
    Torres, Ferran
    Rodriguez-Lope, Carlos
    Forner, Alejandro
    LLarch, Neus
    Rimola, Jordi
    Darnell, Anna
    Rios, Jose
    Ayuso, Carmen
    Bruix, Jordi
    JOURNAL OF HEPATOLOGY, 2014, 61 (02) : 318 - 324
  • [2] Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S).
    Meyers, Daniel E.
    Lee-Ying, Richard M.
    Alghamdi, Mohammed Abdullah
    Cheung, Winson Y.
    Samawi, Haider
    Tam, Vincent C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib
    Branco, Fernanda
    Alencar, Regiane S. M.
    Volt, Fernanda
    Sartori, Giovana
    Dode, Andressa
    Kikuchi, Luciana
    Tani, Claudia M.
    Chagas, Aline L.
    Pfiffer, Tulio
    Hoff, Paulo
    Carrilho, Flair J.
    de Mattos, Angelo Alves
    ANNALS OF HEPATOLOGY, 2017, 16 (02) : 263 - 268
  • [4] Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trial
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Ogawa, Chikara
    Chiba, Yasutaka
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [5] Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events
    Rimola, Jordi
    Diaz-Gonzalez, Alvaro
    Darnell, Anna
    Varela, Maria
    Pons, Fernando
    Hernandez-Guerra, Manuel
    Delgado, Manuel
    Castroagudin, Javier
    Matilla, Ana
    Sangro, Bruno
    Rodriguez de Lope, Carlos
    Sala, Margarita
    Gonzalez, Carmen
    Huertas, Carlos
    Minguez, Beatriz
    Ayuso, Carmen
    Bruix, Jordi
    Reig, Maria
    HEPATOLOGY, 2018, 67 (02) : 612 - 622
  • [6] Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
    Soria, Anna
    Calvo, Mariona
    Casas, Meritxell
    Vidales, Zara
    Munoz-Martinez, Sergio
    Sapena, Victor
    Puigvehi, Marc
    Canillas, Lidia
    Guardeno, Raquel
    Gallego, Adolfo
    Minguez, Beatriz
    Horta, Diana
    Clos, Ariadna
    Montoliu, Silvia
    Roget, Merce
    Reig, Maria
    Vergara, Mercedes
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] SORAFENIB TOLERANCE AND ADVERSE EVENTS IN THE FIRST LINE TREATMENT OF HEPATOCELLULAR CARCINOMA
    Herren, C.
    Beyrer, J. K.
    Chen, L.
    Li, L.
    Heaton, P. C.
    Bowman, L.
    Girvan, A.
    VALUE IN HEALTH, 2017, 20 (05) : A87 - A87
  • [8] Systematic review and metanalysis establish dermatologic adverse events as a positive predictor of survival in hepatocellular carcinoma patients treated with sorafenib
    Diaz-Gonzalez, A.
    Sanduzzi-Zamparelli, M.
    Sapena, V.
    Torres, F.
    Llarch, N.
    Iserte, G.
    Forner, A.
    Da Fonseca, L. G.
    Rios, J.
    Bruix, J.
    Reig, M.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S195 - S195
  • [9] Relationship of ethnicity and overall survival (OS) in Asian patients (pts) on sorafenib for advanced hepatocellular carcinoma (HCC) in British Columbia, Canada
    Peixoto, Renata D'Alpino
    Renouf, Daniel John
    Gill, Sharlene
    Cheung, Winson Y.
    Kennecke, Hagen F.
    Lim, Howard John
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [10] Safety Profile of Sorafenib in Hepatocellular Carcinoma, Could Certain Adverse Events Predict Better Survival?
    Abbas, Ali
    Khullar, Vikas
    Horne, Patrick
    Mills, Rennie
    Cabrera, Roniel
    GASTROENTEROLOGY, 2014, 146 (05) : S993 - S993
12345